XENOGEN IVIS-200 SMALL ANIMAL IMAGING SYSTEM: CANCER

XENOGEN IVIS-200 小动物成像系统：癌症

• 批准号: 7335167
• 负责人: LOUIS James DE TOLLA
• 金额: $ 14.06万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7335167
• 关键词: communicable diseases; medicine; neoplasm /cancer; schools; university

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): In vivo bioluminescence and fluorescence imaging has opened new research avenues, particularly in the fields of cancer research and infectious disease. The Xenogen IVIS-200 biophotonic imaging system is currently the state-of-the-art instrument for conducting such whole animal imaging studies. This application requests funding to purchase a Xenogen IVIS-200 imaging system to benefit the NIH-funded research projects of a core group of 14 listed investigators who are studying both cancer and infectious disease. Use of the Xenogen system by these investigators will account for more than 90% of instrument time. No instrument with comparable imaging capability currently exists in the entire University System of Maryland. The IVIS-200 will be housed in the centrally-located Animal Biosafety Level 2 facility of Howard Hall, and the Program in Comparative Medicine will provide newly-renovated laboratory space for the instrument. In addition, the Program in Comparative Medicine will provide funding for the salary of a Ph.D.-educated, faculty-appointed veterinarian to oversee instrument operation, maintenance and the training of new users. The Principal Investigator of this grant, Louis DeTolla, is the Director of Comparative Medicine and the Chief of Veterinary Resources at the University of Maryland Medical School, and is particularly well-suited to manage this instrument for the benefit of a wide range of investigators with animal research projects. The Institutional Animal Care and Use Committee of the University of Maryland School of Medicine will serve as an internal advisory board for the safe operation of the instrument and equitable access to all listed users. Funding to provide a continuing service contract for on-site technical support and repairs will be supplied by the Greenebaum Cancer Center. The web development office of the Cancer Center will also generate an HTML-based instrument reservation system to facilitate remote time allocation and provide a central record of instrument usage to ensure equitable access. Two of the users (Martin, Winkles) already have practical experience using Xenogen biophotonic imaging systems and have generated preliminary data on their research projects with these systems. Research at the University of Maryland School of Medicine will be greatly enhanced by the availability of a Xenogen IVIS-200, particularly within the Greenebaum Cancer Center and the Mid-Atlantic Regional Center for Excellence in Biodefense and Emerging Infectious Disease.

该子项目是利用由NIH/NCRR资助的共享仪器赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。列出的机构是用于资助的，不一定是研究者的机构。描述（申请人提供）：体内生物发光和荧光成像开辟了新的研究途径，特别是在癌症研究和传染病领域。Xenogen IVIS-200生物光子成像系统是目前进行此类整体动物成像研究的最先进仪器。该申请要求资助购买Xenogen IVIS-200成像系统，以使NIH资助的14名研究人员的核心研究项目受益，这些研究人员正在研究癌症和传染病。这些研究者使用Xenogen系统将占仪器时间的90%以上。在整个马里兰州的大学系统中，目前还没有具有可比成像能力的仪器。IVIS-200将被安置在霍华德大厅位于中心的动物生物安全2级设施中，比较医学计划将为该仪器提供新装修的实验室空间。此外，比较医学计划将为博士的工资提供资金-受过教育的教师指定的兽医监督仪器操作，维护和新用户的培训。该补助金的主要研究者Louis DeTolla是马里兰州医学院比较医学主任和兽医资源主任，特别适合管理该仪器，以造福于各种动物研究项目的研究人员。马里兰州大学医学院的机构动物护理和使用委员会将作为内部咨询委员会，负责仪器的安全操作和所有列出的用户的公平访问。提供现场技术支持和维修的持续服务合同的资金将由Greenebaum癌症中心提供。癌症中心的网络开发办公室还将生成一个基于HTML的仪器预订系统，以促进远程时间分配，并提供仪器使用的中央记录，以确保公平使用。其中两名用户（Martin，Winkles）已经拥有使用Xenogen生物光子成像系统的实际经验，并已使用这些系统生成了其研究项目的初步数据。马里兰州大学医学院的研究将大大加强Xenogen IVIS-200的可用性，特别是在Greenebaum癌症中心和中大西洋地区生物防御和新发传染病卓越中心。